SCHEMBL2089592

SCHEMBL2089592

COc1ccc(NC(=O)C[O])cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.71
ALDH1A1 P00352 4/20 0.67
HTT P42858 1/20 0.67
SMN1; SMN2 Q16637 5/20 0.66
RAB9A P51151 3/20 0.66
NPC1 O15118 2/20 0.66
MAPT P10636 3/20 0.63
HDAC3 O15379 2/20 0.63
HDAC4 P56524 2/20 0.63
HDAC1 Q13547 2/20 0.63
HDAC7 Q8WUI4 2/20 0.63
HDAC2 Q92769 2/20 0.63
HDAC10 Q969S8 2/20 0.63
HDAC11 Q96DB2 2/20 0.63
HDAC8 Q9BY41 2/20 0.63
HDAC6 Q9UBN7 2/20 0.63
HDAC9 Q9UKV0 2/20 0.63
HDAC5 Q9UQL6 2/20 0.63
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9313874 0.88 L3MBTL1 (0.76) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL147292 0.85 L3MBTL1 (0.77) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL2954416 0.85 L3MBTL1 (0.71) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL2089593 0.85 L3MBTL1 (0.71) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL16438801 0.84 L3MBTL1 (0.75) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL482453 0.83 L3MBTL1 (0.69) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL1117828 0.83 L3MBTL1 (0.69) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL8243910 0.83 L3MBTL1 (0.69) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL3360540 0.83 L3MBTL1 (0.69) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL1289638 0.83 L3MBTL1 (0.69) L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 L3MBTL1 2575/4885ALDH1A1 412/4885HTT 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.